[Occurrence of psoriasis in a patient presenting Shulman fasciitis treated with infliximab].
BACKGROUND
Anti-TNFalpha drugs are used in certain rheumatologic and gastrointestinal inflammatory diseases and are also effective in cutaneous psoriasis. Several case reports have recently been published concerning induction of paradoxical psoriasis during the course of anti-TNF therapy. We report a new case involving infliximab used to treat Shulman fasciitis.


METHODS
A 39-year-old woman was treated with infliximab for corticoid-dependent Shulman fasciitis. No personal or familial cutaneous psoriasis was noted in her history. Two months after the third infusion, she developed psoriasis vulgaris and pustular palmoplantar psoriasis which improved under topical corticosteroids. Her psoriatic lesions worsened one month after the first maintenance infusion. Since the Shulman fasciitis was not under control, infliximab was withdrawn and replaced with azathioprine. Six months later, her psoriasis was in remission and the Shulman fasciitis was under control.


CONCLUSIONS
TNFalpha plays an important role in the physiopathology of psoriasis through its action on inflammatory infiltrate, angiogenesis and keratinocyte proliferation. Several studies have reported the efficiency of TNFalpha inhibitors in moderate to severe cutaneous psoriasis. However, fourteen cases of induction or worsening of psoriasis have been reported with these drugs, suggesting a class effect. We report a new case of cutaneous psoriasis induced by infliximab in a patient presenting corticoid-dependent Shulman fasciitis, and we discuss the possible immunological mechanisms responsible for this paradoxical side effect. Other cutaneous lesions have been reported during treatment with TNFalpha inhibitors. The benefits of this treatment on the underlying inflammatory disease must be balanced against the potential cutaneous side effects when deciding whether to continue with anti-TNFalpha treatment.
Cavailhes
A
A
Service de Dermatologie, Centre hospitalier Victor Dupouy, Argenteuil.
Ingen-Housz-Oro
S
S
Djennane
S
S
Rafaa
M
M
Fiszenson-Albala
F
F
Weber
N
N
Sigal-Grinberg
M
M
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003879:Dermatologic Agents / Q000009:adverse effects*; D004487:Edema / Q000139:chemically induced; D005208:Fasciitis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000139:chemically induced; D000069285:Infliximab; D011565:Psoriasis / Q000139:chemically induced*
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab